Therapeutic agents for pancreatic cancer

a technology for pancreatic cancer and compositions, applied in the field of therapeutic compositions for pancreatic cancer, can solve the problems of rapid progress and poor prognosis, early recurrence after, and inability to achieve significant improvement in extended survival of pancreatic cancer patients, and achieve excellent therapeutic effect against pancreatic cancer. , the effect of reducing metastatic lesions of human pancreatic cancer

Inactive Publication Date: 2013-06-13
NAT CANCER CENT +1
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0049]An excellent therapeutic effect against pancreatic cancer was obtained by using an IL-6 inhibitor and an antimetabolite in combination. Moreover, it was shown that metastatic lesio...

Problems solved by technology

It is also used as a combination therapy with radiotherapy, but has not achieved significant improvement in extended survival of pancreatic cancer patients.
Pancreatic cancer is diagnosed at unresectable advanced stages in many cases even today, and associated with rapid progress and very poor prognosis.
Even...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agents for pancreatic cancer
  • Therapeutic agents for pancreatic cancer
  • Therapeutic agents for pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Combined Administration of Gemcitabine Hydrochloride and Tocilizumab on Pancreatic Cancer

[0160]A chemotherapy-naive patient having progressive / metastatic pancreatic cancer and showing CRP>=2.0 mg / dL (CRP: C-reactive protein that correlates with the intensity of inflammatory response) was treated with gemcitabine hydrochloride and a humanized IL-6 receptor antibody (tocilizumab).

[0161]A male at age 72 with no history of smoking having pancreatic body cancer of Stage IV as defined by the TNM classification of UICC1) had metastatic lesions in the liver, lymph nodes, ascites and peritoneum and had evident ascites as shown in FIG. 1. This case had a CRP of 3.28 mg / dL immediately before administration and also suffered from hyperlipidemia and chronic atrophic gastritis as complications. This patient was treated with gemcitabine hydrochloride and tocilizumab in combination. Gemcitabine hydrochloride was administered by intravenous drip injection at 1000 mg / m2 expressed as gemcita...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Login to view more

Abstract

We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an XL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Description

TECHNICAL FIELD[0001]The present invention relates to therapeutic compositions for pancreatic cancer. More specifically, the present invention relates to therapeutic compositions for pancreatic cancer comprising an interleukin 6 (IL-6) inhibitor, said compositions further comprising or being administered in combination with an antimetabolite.BACKGROUND ART[0002]IL-6 is a cytokine also called B cell stimulating factor 2 (BSF2) or interferon β2. IL-6 was discovered as a differentiation factor involved in the activation of B lymphocytes (non-patent document 1), and then demonstrated to be a multifunctional cytokine that influences functions of various cells (non-patent document 2). IL-6 has been reported to induce maturation of T lymphocytes (non-patent document 3).[0003]IL-6 mediates its biological activities through two proteins on cells. One is the IL-6 receptor that is a ligand-binding protein having a molecular weight of about 80 kD to which IL-6 binds (non-patent document 4, non-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61K31/7068
CPCA61K31/7068A61K39/3955A61K45/06C07K2317/24C07K16/2866A61K2300/00A61P1/18A61P35/00A61P43/00A61K2039/505
Inventor MITSUNAGA, SHUICHIOCHIAI, ATSUSHIIKEDA, MASAFUMI
Owner NAT CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap